Innovation competition is not a speculative theory of harm, Csiszár says
Contractual terms in deals between drugmakers show that mergers can change companies’ incentives to innovate, a senior EU competition official has said.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.